335 related articles for article (PubMed ID: 9210041)
21. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.
Pantaleo G; Demarest JF; Vaccarezza M; Graziosi C; Bansal GP; Koenig S; Fauci AS
Eur J Immunol; 1995 Jan; 25(1):226-31. PubMed ID: 7843235
[TBL] [Abstract][Full Text] [Related]
22. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
24. Antibody neutralization and escape by HIV-1.
Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
[TBL] [Abstract][Full Text] [Related]
25. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
Ramirez Valdez KP; Kuwata T; Maruta Y; Tanaka K; Alam M; Yoshimura K; Matsushita S
Virology; 2015 Jan; 475():187-203. PubMed ID: 25486586
[TBL] [Abstract][Full Text] [Related]
26. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains.
Février M; Boudet F; Deslandres A; Theze J
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):491-500. PubMed ID: 7543271
[TBL] [Abstract][Full Text] [Related]
27. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
28. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.
Schreiber M; Wachsmuth C; Müller H; Odemuyiwa S; Schmitz H; Meyer S; Meyer B; Schneider-Mergener J
J Virol; 1997 Dec; 71(12):9198-205. PubMed ID: 9371578
[TBL] [Abstract][Full Text] [Related]
29. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.
Chin LT; Hinkula J; Levi M; Ohlin M; Wahren B; Borrebaeck CA
Immunology; 1994 Mar; 81(3):428-34. PubMed ID: 7515847
[TBL] [Abstract][Full Text] [Related]
30. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
31. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.
VanCott TC; Bethke FR; Polonis VR; Gorny MK; Zolla-Pazner S; Redfield RR; Birx DL
J Immunol; 1994 Jul; 153(1):449-59. PubMed ID: 7515931
[TBL] [Abstract][Full Text] [Related]
32. Simple enzyme immunoassay for titration of antibodies to the CD4-binding site of human immunodeficiency virus type 1 gp120.
Turbica I; Posner M; Bruck C; Barin F
J Clin Microbiol; 1995 Dec; 33(12):3319-23. PubMed ID: 8586727
[TBL] [Abstract][Full Text] [Related]
33. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.
Baum LL; Cassutt KJ; Knigge K; Khattri R; Margolick J; Rinaldo C; Kleeberger CA; Nishanian P; Henrard DR; Phair J
J Immunol; 1996 Sep; 157(5):2168-73. PubMed ID: 8757343
[TBL] [Abstract][Full Text] [Related]
35. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
Moore JP; Ho DD
J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
[TBL] [Abstract][Full Text] [Related]
36. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
37. Studies on the intermolecular forces involved in the antibody-antigen interactions, using V3 synthetic peptides and sera from HIV1 seropositive patients.
Măgureanu CG; Diaconu C; Alexandrescu R; Tirdei G; Cernescu C
Rev Roum Virol; 1994; 45(3-4):143-57. PubMed ID: 7619736
[TBL] [Abstract][Full Text] [Related]
38. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
39. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
[TBL] [Abstract][Full Text] [Related]
40. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
